BMRN stock

Biomarin Pharmaceutical Inc (BMRN) support and resistance · P/E 40, rev $2.85B

Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.

This page maps Biomarin Pharmaceutical Inc (BMRN) support and resistance from cached range and valuation — not a live tape and not a trade alert.

Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.

BMRN currently screens at market cap $10.63B and trailing P/E 39.6. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.

A new BMRN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.

Not investment advice. Use the BMRN quote page for the session range and the stock page for the full model.

Not investment advice.

Full BMRN analysis